MAIA Biotechnology (MAIA) Other Non Operating Income (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Other Non Operating Income of $580277.0 for Q1 2026, down 36.1% year-over-year from $908172.0 in Q1 2025, and up 177.75% quarter-over-quarter from -$746292.0 in Q4 2025.
MAIA Biotechnology (MAIA) Other Non Operating Income (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Other Non Operating Income for 4 consecutive years, with $580277.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 36.1% year-over-year to $580277.0; the TTM figure through Mar 2026 stood at $820583.0 (down 25.0% YoY), while the FY2025 annual figure was $313954.0, down 1.39% from the prior year.
- Other Non Operating Income grew to $580277.0 in Q1 2026 per MAIA's latest filing, from -$746292.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $908172.0 in Q1 2025 and bottomed at -$746292.0 in Q4 2025.
- Historically, Other Non Operating Income has averaged $167741.5 across 3 years, with a median of $92933.0 in 2024.
- On a YoY basis, Other Non Operating Income climbed as much as 26.07% in 2025 and fell as far as 1035.39% in 2025.
- MAIA Biotechnology's Other Non Operating Income stood at $79784.0 in 2024, then tumbled by 1035.39% to -$746292.0 in 2025, then jumped by 177.75% to $580277.0 in 2026.
- Business Quant data shows MAIA's Other Non Operating Income at $580277.0 in Q1 2026, -$746292.0 in Q4 2025, and $78426.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 373,664.00 |
| Mar 31, 2026 | 580,277.00 |
| Dec 31, 2025 | -746,292.00 |
| Sep 30, 2025 | 78,426.00 |
| Mar 31, 2025 | 908,172.00 |
| Dec 31, 2024 | 79,784.00 |
| Sep 30, 2024 | 106,082.00 |
| Sep 30, 2021 | -2.32 Mn |